close

Enter

Log in using OpenID

Human Milk Oligosaccharides (HMO) Market Share

embed
The global human milk oligosaccharides (HMO) market size is expected to reach USD 170.4 million by 2024.
Your Catalyst To a Lucrative Business
Human Milk Oligosaccharides (HMO) Market Size, Share, Growth,
Trends, Outlook and Forecast to 2024 | Hexa Research
“The global Human Milk Oligosaccharides (HMO)
market size was valued at USD 60.0 million in 2015
and is expected to grow further over the forecast
period.”
11 October 2018 –
The global Human Milk Oligosaccharides (HMO) Market size is expected to reach USD 170.4 million by 2024. It is
anticipated to expand at a CAGR of 12.3% over the forecast period.HMO is a bioactive complex sugar molecule,
which promotes growth of healthy bacteria, such as bifid bacteria genus in human gut. It also and helps improve
metabolic activity in human body. In addition, incorporation of HMO in the formulation of functional foods and
beverages not only promotes growth of healthy bacteria but also eliminates harmful microbes such as salmonella,
listeria, and campylobacter.
High infant mortality rate coupled with rising demand for human milk donors in North America is one of the major
drivers for the HMO market. North America accounted for around 25.0% of global market share in 2015 and is
projected to expand further during the forecast period. Growing demand for infant food especially for infants with
non-lactating mothers coupled with strong presence of infant formula manufacturers in U.S. is expected to have a
positive impact on regional market. Besides North America, Europe is one of the key markets for human milk
oligosaccharides. Presence of a large biotechnical institutes engaged in the development of enzyme formulations in
Germany, U.K., and France is encouraging HMO manufacturers to establish tie-ups to improve their R&D activities.
Browse Details of Report @ https://www.hexaresearch.com/research-report/human-milk-oligosaccharideshmo-market
Follow Us:
Your Catalyst To a Lucrative Business
Over the past few years, many R&D institutes have launched chemically synthesizing techniques and cow milk
processing methods for the production of HMO. Extraction of human milk oligosaccharides is a bit expensive due to
the limited access to raw materials. Product innovations aimed at improving brain health, are expected to pose a
threat to the existing market participants. According to the World Health Organization (WHO), the world
population is expected rise by over a billion in the next 10 years. This factor is anticipated to propel demand for
infant food, thereby driving the global market.
The HMO is also useful for adults as it helps maintain health of the digestive system. The ingredient acts as a
microbiota modulator and maintains health of the immune system. HMO also helps prevent T1D, which interacts
between the innate immune system and intestinal microbes in adults. High demand for digestive health
supplements among adults due to rising concerns regarding gastrointestinal disorders is expected to promote
market growth.
Some of the key manufacturers in the Human Milk Oligosaccharides (HMO) market include Inbiose; Jennewein
Biotechnologie GmbH; Elicityl SA; Glycom A/S; ZuChem, Inc.; Medolac Laboratories; and Glycosyn LLC. Increased
number of health claims in U.S. and several developed markets of Europe has spurred studies to explore the
potential of HMO. These studies have derived different microbial challenges in gut, prevention of diarrhea, and
protection from infectious diseases. In September 2013, ZuChem launched new HMO formulations including lgalactose, as well as sugar phosphates such as β-l-glucose-1-phosphate, α-d-galactose-1-phosphate, and β-l-xylose1-phosphate. In October 2014, U.S. based Madolac Laboratories completed construction of second phase of HMO
purification plant. This plant will synthesize human milk oligosaccharides on a large scale, which will be further
used in clinical trials and scientific research.
Hexa Research has segmented the global human milk oligosaccharides (HMO) market report based on application
and region:Segmentation by Application
• Infant Formula
• Functional Food & Beverages
• Food Supplements
• Others
Segmentation by Region
• North America
• U.S.
• Europe
• U.K.
• Germany
• Asia Pacific
• China
Follow Us:
Your Catalyst To a Lucrative Business
• Japan
• Latin America
• Brazil
• MEA
Key players analyzed:
• Inbiose NV
• Elicityl S.A.
• Jennewein Biotechnologie GmbH
• Glycom A/S
• Medolac Laboratories
• ZuChem Inc.
• Glycosyn LLC
Browse Related Category Market [email protected] https://www.hexaresearch.com/researchcategory/nutraceuticals-and-functional-foods-industry
Follow Us:
Your Catalyst To a Lucrative Business
Table of Content of Human Milk Oligosaccharides (HMO) Market
Chapter 1 Research Methodology
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 HMO Industry Outlook
3.1 HMO Market Segmentation
3.2 HMO Market Size and Growth Prospects, 2013 - 2024
3.3 HMO - Value Chain Analysis
3.3.1 Vendor Landscape
3.4 Raw material Outlook
3.5 Technology Overview
3.6 Regulatory Framework
3.6.1 European Commission: Regulation (EC) No 258/97 of the European Parliament
3.7 HMO Market Dynamics
3.7.1 Market Driver Analysis
3.7.1.1 Positive Dairy Industry Outlook
3.7.1.2 Growing Dietary Supplements Market
3.7.1.3 Rising Concerns Towards Gut Health
3.7.2 Market Restraints Analysis
3.7.2.1 Lack of Technology for Large-scale Production
3.7.2.2 High R&D Cost
3.8 Key Opportunities Prioritized
3.9 HMO Competitive Landscape
3.10 HMO Porter’s Analysis
3.11 HMO Market PESTEL Analysis
3.12 Pricing Trends 2013 – 2024
Chapter 4 HMO Product Outlook
4.1 2’-Fucosyllactose (2’FL)
4.1.1 Specifications
4.1.2 Key Suppliers
Follow Us:
Your Catalyst To a Lucrative Business
4.1.3 Applications
4.1.4 Patents
4.1.5 Production Routes
4.1.6 Manufacturers
4.2 3’-Fucosyllactose (3’FL)
4.2.1 Specifications
4.2.2 Key Suppliers
4.2.3 Applications
4.2.4 Patents
4.2.5 Production Routes
4.2.6 Manufacturers
4.3 3’-Sialyllactose (3’SL)
4.3.1 Specifications
4.3.2 Key Suppliers
4.3.3 Application
4.3.4 Patents
4.3.5 Production Routes
4.3.6 Manufacturers
4.4 6’-Sialyllactose (6’SL)
4.4.1 Specifications
4.4.2 Key Suppliers
4.4.3 Applications
4.4.4 Patents
4.4.5 Production Routes
4.4.6 Manufacturers
4.5 Lacto-N-tetraose (LNT)
4.5.1 Specifications
4.5.2 Key Suppliers
4.5.3 Patents
4.5.4 Applications
4.5.5 Production Routes
4.5.6 Manufacturers
4.6 Lacto-N-neotetraose (LNnT)
4.6.1 Specifications
4.6.2 Key Suppliers
4.6.3 Patents
Follow Us:
Your Catalyst To a Lucrative Business
4.6.4 Applications
4.6.5 Production Routes
4.6.6 Manufacturers
Chapter 5 HMO Application Outlook
5.1 Global HMO Market Volume Share by Application, 2015 & 2024
5.2 Infant Formula
5.2.1 Global HMO Market Estimates and Forecast in Infant Formula, 2013 - 2024 (Grams) (USD
000)
5.2.2 Global HMO Market Estimates and Forecast in Infant Formula, by Region, 2013 - 2024
(Grams) (USD 000)
5.3 Functional Food & Beverages
5.3.1 Global HMO Market Estimates and Forecast in Functional Food & Beverages, 2013 - 2024
(Grams) (USD 000)
5.3.2 Global HMO Market Estimates and Forecast in Functional Food & Beverages, by region,
2013 - 2024 (Grams) (USD 000)
5.4 Food Supplements
5.4.1 Global HMO Market Estimates and Forecast in Food Supplements, 2013 - 2024 (Grams)
(USD 000)
5.4.2 Global HMO Market Estimates and Forecast in Food Supplements, by Region, 2013 - 2024
(Grams) (USD 000)
5.5 Others
5.5.1 Global HMO Market Estimates and Forecast in Other Applications, 2013 - 2024 (Grams)
(USD 000)
5.5.2 Global HMO Market Estimates and Forecast in Other Applications, by Region, 20 13 - 2024
(Grams) (USD 000)
Chapter 6 HMO Regional Outlook
6.1 Global HMO Market Volume Share by Region, 2015 & 2024
6.2 North America
6.2.1 North America HMO Market Estimates and Forecast, 2013 - 2024 (Grams) (USD 000)
6.2.2 North America HMO Market Estimates and Forecast, by Application, 2013 - 2024 (Grams)
(USD 000)
6.2.3 U.S.
6.2.3.1 U.S. HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000)
6.2.3.2 U.S. HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD
Follow Us:
Your Catalyst To a Lucrative Business
000)
6.3 Europe
6.3.1 Europe HMO market estimates and forecast, 2012-2020 (Grams) (USD 000)
6.3.2 Europe HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD
000)
6.3.3 U.K.
6.3.3.1 U.K. HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000)
6.3.3.2 U.K. HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD
000)
6.3.4 Germany
6.3.4.1 Germany HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000)
6.3.4.2 Germany HMO market estimates and forecast, by application, 2013 - 2024 (Grams)
(USD 000)
6.4 Asia Pacific
6.4.1 Asia Pacific HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000)
6.4.2 Asia Pacific HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD
000)
6.4.3 China
6.4.3.1 China HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000)
6.4.3.2 China HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD
000)
6.4.4 Japan
6.4.4.1 Japan HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000)
6.4.4.2 Japan HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD
000)
6.5 Latin America
6.5.1 Latin America HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000)
6.5.2 Latin America HMO market estimates and forecast, by application, 2013 - 2024 (Grams)
(USD 000)
6.5.3 Brazil
6.5.3.1 Brazil HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000)
6.5.3.2 Brazil HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD
000)
6.6 MEA
6.6.1 MEA HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000)
6.6.2 MEA HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD 000)
Follow Us:
Your Catalyst To a Lucrative Business
Chapter 7 Competitive Landscape
7.1 Inbiose NV
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Elicityl S.A.
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Jennewein Biotechnologie GmbH
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Glycom A/S
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.5 Medolac Laboratories
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
7.6 ZuChem Inc.
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Glycosyn LLC
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
Follow Us:
Your Catalyst To a Lucrative Business
About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research
and consulting services to a host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients obtain clarity about their business
environment and enable them to undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: [email protected]
Website - https://www.hexaresearch.com
Follow Us:
Author
sara01.james
sara01.james342   documents Email
Document
Category
Cooking and Food
Views
1
File Size
1 052 KB
Tags
milk, Human Milk Oligosaccharides Market
1/--pages
Report inappropriate content